About the Company

Granules India Limited is a vertically integrated pharmaceutical company incorporated in 1991, with a legacy spanning four decades of developing, manufacturing and selling Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages (FDs). The company serves over 300 customers across more than 80 countries, with North America as its largest market by revenue, followed by Europe, Latin America and AMEA . Operations are anchored in India and the United States, supported by global R&D capabilities and a growing innovation pipeline .

Granules supplies 100+ molecules and maintains large-scale manufacturing across APIs, PFIs and oral solid dosages. Its footprint includes facilities in Telangana, Andhra Pradesh and Virginia, USA, with packaging and R&D centres complementing the network . As of March 31, 2025, the Group disclosed six subsidiaries, including Indian and overseas entities, in its consolidated notes and statutory subsidiary filings  .

Key milestones in the latest year included operationalising the Genome Valley site with an initial 2.5 billion-dosage capacity, scalable to 10 billion, and a targeted investment of Rs 150 crore to expand API capacity at Unit V. The company also incorporated Granules Peptides Private Limited in March 2025 to facilitate the acquisition of a Switzerland-based peptide specialist, marking an entry into custom peptide development and manufacturing .

Business Segments

– Finished Dosages (FD): The FD segment remained the primary revenue contributor, accounting for 77% of total revenues in FY 2024-25 (up from 65% in FY 2023-24) .

– Geographical revenue mix: North America 77%; Europe 10%; India 5%; Latin America 5%; Remaining from Rest of World. 

Key Management

– Dr. Krishna Prasad Chigurupati – Chairman and Managing Director

– Dr. K. V. S. Ram Rao – Joint Managing Director & Chief Executive Officer

– Mrs. Uma Devi Chigurupati – Executive Director

– Mr. Harsha Chigurupati – Executive Director

– Mrs. Priyanka Chigurupati – Executive Director

– Mr. Mukesh Surana – Chief Financial Officer

– Ms. Chaitanya Tummala – Company Secretary

Latest Updates

– Regulatory milestones and launches: Granules received six ANDA approvals from the USFDA in FY 2024-25, underscoring filing quality. New approvals included Colchicine Capsules, with commercial launches for Colchicine and Esomeprazole in the US, and one application in Canada  .

– Capacity expansion: The Genome Valley FD site was operationalised (2.5 billion dosages in Phase I, scalable to 10 billion), and the company invested Rs 150 crore to expand API capacity at Unit V, reinforcing manufacturing scalability and resilience .

– Strategic move into peptides: Granules Peptides Private Limited was incorporated in March 2025 for acquiring 100% equity in a Switzerland-based custom peptide manufacturer, expanding Granules’ presence into peptide development and manufacturing .

– Portfolio and market focus: The company maintained strong momentum in formulations, particularly in North America, even as API and PFI volumes were affected by pricing pressure and customer inventory levels .